SGS-742 Novartis

Curr Opin Investig Drugs. 2005 Jan;6(1):108-13.

Abstract

SGS-742, a GABA(B) antagonist, is being developed by Saegis, under license from Novartis, for the potential treatment of mild cognitive impairment and Alzheimer's disease (AD). In May 2004, Saegis began enrollment in a phase II trial of SGS-742 in mild-to-moderate AD patients.

Publication types

  • Review

MeSH terms

  • Alzheimer Disease / drug therapy*
  • Alzheimer Disease / metabolism
  • Animals
  • Attention Deficit Disorder with Hyperactivity / drug therapy*
  • Attention Deficit Disorder with Hyperactivity / metabolism
  • Clinical Trials as Topic
  • Cognition Disorders / drug therapy*
  • Cognition Disorders / metabolism
  • GABA Antagonists* / adverse effects
  • GABA Antagonists* / pharmacokinetics
  • GABA Antagonists* / therapeutic use
  • Humans
  • Organophosphorus Compounds* / adverse effects
  • Organophosphorus Compounds* / pharmacokinetics
  • Organophosphorus Compounds* / therapeutic use

Substances

  • GABA Antagonists
  • Organophosphorus Compounds
  • (3-aminopropyl)(n-butyl)phosphinic acid